Navigation Links
FASgen Announces New Discovery for Treatment of Stroke
Date:12/20/2007

BALTIMORE, Dec. 20 /PRNewswire/ -- FASgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen's proprietary compounds, C75. The Company is a leader in the research in the field of FASi (fatty acid synthase inhibition). One area of that research has been for the treatment of metabolic disease disorders, including obesity. As the regulation of appetite is centered in the hypothalamus in the brain, research was undertaken to evaluate the safety of the Company's compounds in the brain. An unexpected and significant discovery resulted when the studies demonstrated not only that the compounds were non-toxic in the brain, but also they had the positive effect of providing significant neuroprotection in the case of ischemic stroke. In the stroke models tested, the Company's compound C-75 reduced AMPK levels and resulted in neuroprotection by reduced stroke damage, even when administered poststroke. These remarkable findings were recently published in the article, "Neuroprotective Effects of Adenosine Monophosphate-Activated Protein Kinase Inhibition and Gene Deletion in Stroke," McCullough et al, Stroke 2007, 38; 2992-2999 (December 11, 2007).

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com


'/>"/>
SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2018)... ... December 05, 2018 , ... WHO: The Institute for Healthcare Improvement ... of four keynote addresses and five spotlight sessions taking place during the 30th annual ... and speakers) , WHEN: Beginning Tuesday, December 11 ( full schedule ) , ...
(Date:12/5/2018)... ... December 04, 2018 , ... Florida Hospital West ... and quality. Today, the prestigious Leapfrog Group, a national nonprofit health care ratings ... Hospital Heartland Medical Center Sebring, Florida Hospital Wesley Chapel and Florida Hospital Zephyrhills ...
(Date:12/5/2018)... ... 05, 2018 , ... Two women with a vision to make the blind ... , Jean Bennett, M.D., Ph.D., and Katherine A. High, M.D., whose work with the ... 4 at Sanford Health, headquartered in Sioux Falls, South Dakota. , “I want ...
Breaking Medicine Technology:
(Date:12/6/2018)... ... 2018 , ... HMP, a leader in healthcare events and ... will take place May 9–10, 2019, and will be co-located with the Symposium ... , PACS is uniquely designed to provide nurses with the important tools they ...
(Date:12/6/2018)... ... 06, 2018 , ... Pulse8’s Senior Director of Quality Products, ... Blue Shield of Kansas City, will present on “Boosting Stars Scores by Better ... at the Fairmont Grand Del Mar in San Diego, California. , During ...
(Date:12/5/2018)... and DALLAS, Texas (PRWEB) , ... December 05, ... ... again proved its leading SkinPen Precision device is setting a new standard as ... record-setting Aesthetics Everything win. , Each year this award is presented at the ...
(Date:12/5/2018)... ... December 05, 2018 , ... A well-known name in ... content to the masses. Wellbeats , which has delivered on-demand, virtual fitness programming ... Wellbeats consumer app. Available now in the Apple App Store, the Wellbeats app ...
(Date:12/5/2018)... ... 05, 2018 , ... Advanced Clinical, a clinical research ... office location in Paris, France during the Partnerships in Clinical Trials Europe conference. ... and additional in-country personnel. , “The new office broadens our CRO and FSP ...
Breaking Medicine News(10 mins):